Financial Results : SPIMACO turns to losses of SAR 481 mln in FY 2019

SPIMACO turns to losses of SAR 481 mln in FY 2019

31/03/2020 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) reported a net loss after Zakat and tax of SAR 481 million for the fiscal year 2019 compared to a net profit of SAR 51 million a year earlier.

 

The losses were attributed to a decline in the gross profit of some subsidiaries and increase in impairment losses on trade receivables, In addition, an associate widened impairment losses in the same period.



Financials (M)

Item 2018 2019 Change‬
Revenues 1,503.32 1,486.85 (1.1 %)
Gross Income 608.52 497.64 (18.2 %)
Operating Income 21.00 (80.10) (481.5 %)
Net Income 76.58 (439.74) (674.2 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 0.64 (3.66) (674.2 %)

In Q4 2019, the company net loss after Zakat and tax widened to SAR 312.6 million.

 

SPIMACO’s accumulated losses stood at SAR 278.46 million.



Current Quarter Comparison (M)

Compared With The
Item Q4 2018 Q4 2019 Change‬
Revenues 600.79 344.32 (42.7 %)
Gross Income 127.79 79.28 (38.0 %)
Operating Income (48.39) (78.77) (62.8 %)
Net Income 19.01 (259.65) (1466.1 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 0.16 (2.16) (1466.1 %)

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.